← Back to patent-cliff list
Deucrictibant
Tier C — Watch / tradeDeucrictibant
Pharvaris Netherlands BV
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：BKR2
Indications (approved)：遗传性血管性水肿, 血管性水肿, 遗传性血管性水肿Ⅲ型, 遗传性血管性水肿Ⅰ和Ⅱ型
Regional status
US
Phase III
2022-12-28
EU
Phase III
2022-12-28
China
Phase III
2025-02-01
Japan
Phase III
2022-12-28
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Deucrictibant?
Approved indications include: 遗传性血管性水肿, 血管性水肿, 遗传性血管性水肿Ⅲ型, 遗传性血管性水肿Ⅰ和Ⅱ型.
When does the Deucrictibant patent expire?
No public expiry year is available for Deucrictibant yet; this page updates once verified.
How do I get a quote for Deucrictibant intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21